abrdn Life Sciences Investors (NYSE:HQL) Short Interest Up 70.9% in August

abrdn Life Sciences Investors (NYSE:HQL) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 100,177 shares, an increase of 70.9% from the August 15th total of 58,626 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily volume of 160,266 shares, the short-interest ratio is currently 0.6 days.

abrdn Life Sciences Investors Stock Down 1.1%

abrdn Life Sciences Investors stock traded down $0.23 during midday trading on Friday, hitting $19.34. 33,039 shares of the stock were exchanged, compared to its average volume of 129,538. abrdn Life Sciences Investors has a 52-week low of $14.06 and a 52-week high of $22.67. The business’s 50-day moving average price is $20.39 and its 200-day moving average price is $18.55.

abrdn Life Sciences Investors Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Monday, August 24th will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 12.8%. The ex-dividend date is Monday, August 24th.

Institutional Trading of abrdn Life Sciences Investors

A number of institutional investors and hedge funds have recently modified their holdings of the business. KPP Advisory Services LLC boosted its holdings in abrdn Life Sciences Investors by 2.7% during the 2nd quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock valued at $505,000 after acquiring an additional 660 shares during the period. Uhlmann Price Securities LLC increased its stake in abrdn Life Sciences Investors by 2.3% in the 1st quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company’s stock worth $1,267,000 after purchasing an additional 1,719 shares during the period. 180 Wealth Advisors LLC lifted its position in abrdn Life Sciences Investors by 2.2% in the second quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after purchasing an additional 3,271 shares during the last quarter. NewEdge Advisors LLC lifted its position in abrdn Life Sciences Investors by 17.6% in the first quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock valued at $387,000 after purchasing an additional 3,562 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in shares of abrdn Life Sciences Investors by 4.2% during the first quarter. Janney Montgomery Scott LLC now owns 91,519 shares of the company’s stock valued at $1,489,000 after purchasing an additional 3,666 shares during the period. 32.21% of the stock is owned by hedge funds and other institutional investors.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE:HQL) is a non-diversified, closed-end investment company focused on the global life sciences sector. The fund seeks long-term capital appreciation by investing in companies involved in biotechnology, pharmaceuticals, medical devices, healthcare services and other related industries.

The fund may invest in both publicly traded and privately held companies across various stages of development, including businesses developing innovative therapies, diagnostic technologies and other healthcare products.